# A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

> **NCT04324996** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chongqing Public Health Medical Center** · enrollment: 90 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells

## Key facts

- **NCT ID:** NCT04324996
- **Lead sponsor:** Chongqing Public Health Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-21
- **Primary completion:** 2022-02-20
- **Final completion:** 2022-08-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324996, "A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04324996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*